Phaseline

Targets › ADORA1

ADORA1 (Adenosine receptor A1): drug programs, companies and trials

19 programs from 19 companies in 28 trials: 11 Phase 4, 7 Phase 2, 7 Phase 1, 3 Phase 3; Other, Cardiovascular, Respiratory; next expected readout Dec 2026.

Receptor for adenosine. The activity of this receptor is mediated by G proteins such as GNAI2 which inhibit adenylyl cyclase. (UniProt, P30542)

Open in Phaseline: the race on ADORA1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Region SkaneAdenosine
Adenosine receptor agonist
ADORA1, ADORA2B, ADORA3, ADORA2APhase 4Chronic Coronary SyndromeDec 2026
National Institute of Cardiovascular Diseases, PakistanAdenosine
Adenosine receptor agonist
ADORA1, ADORA2B, ADORA3, ADORA2APhase 4ST-Segment Elevation Myocardial Infarction (STEMI)Dec 2026
University of Alabama at BirminghamCaffeine citrate
Adenosine receptor antagonist
ADORA1, ADORA2B, ADORA3, ADORA2APhase 4Premature Infant DiseaseMay 2027
Anne E. Zepeskiadenosine
Adenosine receptor agonist
ADORA1, ADORA2B, ADORA3, ADORA2APhase 4Supraventricular Tachycardia (SVT)Jul 2027
Semmelweis UniversityCaffeine citrate
Adenosine receptor antagonist
ADORA1, ADORA2B, ADORA3, ADORA2APhase 4Apnea of PrematurityDec 2027
Weill Medical College of Cornell UniversityAdenosine
Adenosine receptor agonist
ADORA1, ADORA2B, ADORA3, ADORA2APhase 4Premature Ventricular Contraction (PVC)Dec 2027
Vastra Gotaland RegionAdenosine
Adenosine receptor agonist
ADORA1, ADORA2B, ADORA3, ADORA2APhase 4Takotsubo SyndromeDec 2028
RDC ClinicalCaffeine
Adenosine receptor antagonist
ADORA1, ADORA2B, ADORA3, ADORA2APhase 4Exercise; Migraine; Healthy; Vibration Therapy …–
NICHD Global Network for Women's and Children's HealthCaffeine Citrate
Adenosine receptor antagonist
ADORA1, ADORA2B, ADORA3, ADORA2APhase 3Hypoxic Ischemic Encephalopathy (HIE)Dec 2029
Rashid Latif Medical CollegeAdenosine
Adenosine receptor agonist
ADORA1, ADORA2B, ADORA3, ADORA2APhase 3Supraventricular Tachycardia (SVtach)–
New York Medical CollegeDefibrotide
Adenosine A2 receptor agonist; Plasminogen activator; Adenosine A1 receptor agonist
ADORA2B, ADORA2A, PLG, ADORA1, F2Phase 2Sickle Cell Disease; Sinusoidal Obstruction SyndromeDec 2026
Ministry of Health, Saudi ArabiaCaffeine citrate
Adenosine receptor antagonist
ADORA1, ADORA2B, ADORA3, ADORA2APhase 2PrematurityOct 2027
University of RochesterCaffeine Citrate
Adenosine receptor antagonist
ADORA1, ADORA2B, ADORA3, ADORA2APhase 2Neonatal ApneaJul 2028
University of Wisconsin, MadisonCaffeine citrate
Adenosine receptor antagonist
ADORA1, ADORA2B, ADORA3, ADORA2APhase 2Kidney InjuryMar 2030
Indiana UniversityCaffeine citrate
Adenosine receptor antagonist
ADORA1, ADORA2B, ADORA3, ADORA2APhase 1Preterm Labor With Preterm DeliveryJun 2027
University of ChicagoCaffeine citrate
Adenosine receptor antagonist
ADORA1, ADORA2B, ADORA3, ADORA2APhase 1Enhanced Recovery After Surgery in a Pediatric PopulationDec 2027
University of North Carolina, Chapel HillCaffeine Citrate
Adenosine receptor antagonist
ADORA1, ADORA2B, ADORA3, ADORA2APhase 1Hypoxic-Ischemic EncephalopathyJul 2028
McMaster UniversityAdenosine
Adenosine receptor agonist
ADORA1, ADORA2B, ADORA3, ADORA2APhase 1Chronic Cough (CC)–
Nishtar Medical UniversityCaffeine Citrate
Adenosine receptor antagonist
ADORA1, ADORA2B, ADORA3, ADORA2APhase 1Apnea of Prematurity–

Conditions

Apnea of Prematurity (3) Hypoxic-Ischemic Encephalopathy (2) Supraventricular Tachycardia (SVT) (1) Premature Infant Disease (1) Sickle Cell Disease (1) Sinusoidal Obstruction Syndrome (1) Exercise (1) Migraine (1) Healthy (1) Vibration Therapy (1) Alzheimer Disease (1) Carcinoma Breast (1)

Modalities

small molecule (17), protein or peptide (1)

Companies

Anne E. Zepeski (1) Semmelweis University (1) University of Alabama at Birmingham (1) New York Medical College (1) RDC Clinical (1) Weill Medical College of Cornell University (1) Vastra Gotaland Region (1) University of Chicago (1) McMaster University (1) Region Skane (1) Indiana University (1) Ministry of Health, Saudi Arabia (1) NICHD Global Network for Women's and Children's Health (1) National Institute of Cardiovascular Diseases, Pakistan (1) University of Wisconsin, Madison (1) Rashid Latif Medical College (1) Nishtar Medical University (1) University of Rochester (1) University of North Carolina, Chapel Hill (1)

Related targets

ADORA2B (19) ADORA2A (19) ADORA3 (18) PLG (1) F2 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.